Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [518]

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma...

Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye ( Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA )

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients...

Dr Mario Sznol - Yale Cancer Center New Haven, USA

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma ( Dr Mario Sznol - Yale Cancer Center New Haven, USA )

Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

Prevention of squamous cell carcinoma

Dr Kenneth Tsai - MD Anderson Cancer Center, Houston, USA

Prevention of squamous cell carcinoma ( Dr Kenneth Tsai - MD Anderson Cancer Center, Houston, USA )

Immunotherapy in melanoma and other cancers

Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA

Immunotherapy in melanoma and other cancers ( Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA )

Intermittent treatment with vemurafenib may prevent lethal drug resistance in...

Dr Darrin Stuart - Novartis Institutes for Biomedical Research, Emeryville, CA...

Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma ( Dr Darrin Stuart - Novartis Institutes for Biomedical Research, Emeryville, CA, USA )

History of epidermal stem cell use in the clinical setting

Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy

History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )

Analysing the efficacy of treatment through Response Evaluation Criteria in...

Dr Yves Menu – Saint Antoine Hospital, Paris, France

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )

Phase III MISSION trial: Sorafenib does not extend overall survival as third or...

Dr Tony Mok – The Chinese University of Hong Kong

Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer ( Dr Tony Mok – The Chinese University of Hong Kong )

Trametinib and dabrafenib combination therapy against metastatic melanoma

Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia

Trametinib and dabrafenib combination therapy against metastatic melanoma ( Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia )

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib...

Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma ( Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia )

Phase I and II trials focus on drug combination slowing development of...

Prof Yossef Yarden - Weizmann Institute of Science, Israel.

Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF ( Prof Yossef Yarden - Weizmann Institute of Science, Israel. )

More from ecancer